| Product Name | Ubidecarenone - Impurity B |
| Product Code | DA-U001-h |
| Chemical name | Ubiquinone-7 |
| Synonyms | 2-[(all-E)-3,7,11,15,19,23,27-heptamethyloctadocosa-2,6,10,14,18,22,26-heptaenyl]-5,6-dimethoxy-3-methylbenzene-1,4-dione; 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptaen-1-yl]-5,6-dimethoxy-3-methyl; 2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; Coenzyme Q7; trans-Coenzyme Q7; Ubiquinone 35; Ubiquinone Q7; |
| Impurity | NA |
| CAS Number | 303-95-7 |
| Alternate CAS # | NA |
| Molecular form | C44H66O4 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 659.01 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | glycerols,fatty acids derivatives,lipids |
| Boiling Point | NA |
| Applications | An isoprenoid quinone that siginificantly reduced blood sugar and ketone bodies of diabetics. It has been shown to decrease high blood citrate level in humans with periodontal disease. It is a viable therapeutic agent for muscular dystrophy. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
